AIM Rule 17 Notice

RNS Number : 4650O
Immupharma PLC
18 August 2017
 

                                                                                                                                                                     18 August 2017

 

 

 

ImmuPharma Plc

 

AIM Rule 17 Notice

 

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:

 

Tim McCarthy, the Company's Non-executive Chairman, previously held roles on the boards of Alizyme Plc and its subsidiary Alizyme Therapeutics Ltd, both of which entered into a Creditors Voluntary Winding-up in December 2009, within 12 months of his resignation.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Ends

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman


Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

Northland Capital Partners Limited (NOMAD & Broker)

Patrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance

Rob Rees, Corporate Broking

+44 (0)20 3861 6625








 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCOKFDKABKDOFD

Companies

Immupharma (IMM)
UK 100

Latest directors dealings